Sign Out
No clinically significant drug interactions found. Compounds that have been studied in clinical trials include Cimetidine, Warfarin, Furosemide, Digoxin, Atenolol, Indomethacin, Hydrochlorothiazide, Amlodipine and Glibenclamide.
Valsartan is not metabolized to significant, clinically relevant interactions between drugs in the cytochrome P450 system with valsartan are not expected. Although valsartan is strongly bound to plasma proteins, at the in vitro test level it does not show interactions with various molecules that are also strongly bound to plasma proteins such as Diclofenac, Furosemide and warfarin.
Potassium: Concurrent use of potassium-sparing diuretics (for example: Spironolactone, triamterene, amloride), potassium supplements or a potassium salt substitute can cause an increase in serum potassium. If a combination of drugs is considered necessary, caution is recommended.
NSAIDs include selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): When the angiotensin II antagonist drug is given continuously with NSAIDs, attenuation from hypertension can occur. Also to elderly patients, volume-deplete (including administration of diuretic therapy), or patients who have abnormalities in kidney function, concomitant use with angiotensin II antagonists and NSAIDs can increase the risk of kidney damage. Therefore, monitoring of renal function is recommended when starting or modifying treatment in patients taking Valsartan and NSAIDs simultaneously.
